Apellis Pharmaceuticals Competitors and Similar CompaniesClear all

Apellis Pharmaceuticals's competitors and similar companies include Reata Pharmaceuticals, Cipla, Mankind Pharma and EMS Pharma.

	Apellis Pharmaceuticals Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds.	Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines.	EMS Pharma EMS Pharma is a company that specializes in the research, development, and manufacturing of pharmaceuticals.
Founding Date	Founding Date 2009	Founding Date 2002	Founding Date 1935	Founding Date 1995	Founding Date 1964
Type	Type Public	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Waltham, US HQ Kew East, AU München, DE Zug, CH San Francisco, US Watertown, US	Locations Plano, US HQ Irving, US Plano, US	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations New Delhi, IN HQ	Locations BR HQ
Employees	Employees 7028% decrease	Employees 3217% decrease	Employees 27,764	Employees 16,2532% increase	Employees 12,7441% increase
Valuation ($)	Valuation ($) 3.3 b	Valuation ($) 6.6 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $1b (FY, 2025)	Revenue (est.) $2.2m (FY, 2022)	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) N/A
Net income	Net income $22.4m (FY, 2025)	Net income ($311.9m) (FY, 2022)	Net income ₹38.7b (FY, 2026)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 88m	Total funding raised $ 468.9m	Total funding raised N/A	Total funding raised $ 239m	Total funding raised N/A